Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types

Lydia J. Atherton; Patricia A. Jorquera; Abhijeet A. Bakre; Ralph A. Tripp

doi:10.3389/fimmu.2019.02323

Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types

Lydia J. Atherton, Patricia A. Jorquera, Abhijeet A. Bakre, Ralph A. Tripp

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

14 Downloads (Pure)

Abstract

Respiratory Syncytial Virus (RSV) causes serious respiratory tract illness and substantial morbidity and some mortality in populations at the extremes of age, i.e., infants, young children, and the elderly. To date, RSV vaccine development has been unsuccessful, a feature linked to the lack of biomarkers available to assess the safety and efficacy of RSV vaccine candidates. We examined microRNAs (miR) as potential biomarkers for different types of RSV vaccine candidates. In this study, mice were vaccinated with a live attenuated RSV candidate that lacks the small hydrophobic (SH) and attachment (G) proteins (CP52), an RSV G protein microparticle (GA2-MP) vaccine, a formalin-inactivated RSV (FI-RSV) vaccine or were mock-treated. Several immunological endpoints and miR expression profiles were determined in mouse serum and bronchoalveolar lavage (BAL) following vaccine priming, boost, and RSV challenge. We identified miRs that were linked with immunological parameters of disease and protection. We show that miRs are potential biomarkers providing valuable insights for vaccine development.

Original language	English
Article number	2323
Pages (from-to)	1-16
Number of pages	16
Journal	Frontiers in Immunology
Volume	10
DOIs	https://doi.org/10.3389/fimmu.2019.02323
Publication status	Published - 9 Oct 2019
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fimmu.2019.02323Licence: CC BY

ArticleFinal published version, 1.43 MBLicence: CC BY

Cite this

@article{581a528da55d441ab71d038b8de71e41,

title = "Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types",

abstract = "Respiratory Syncytial Virus (RSV) causes serious respiratory tract illness and substantial morbidity and some mortality in populations at the extremes of age, i.e., infants, young children, and the elderly. To date, RSV vaccine development has been unsuccessful, a feature linked to the lack of biomarkers available to assess the safety and efficacy of RSV vaccine candidates. We examined microRNAs (miR) as potential biomarkers for different types of RSV vaccine candidates. In this study, mice were vaccinated with a live attenuated RSV candidate that lacks the small hydrophobic (SH) and attachment (G) proteins (CP52), an RSV G protein microparticle (GA2-MP) vaccine, a formalin-inactivated RSV (FI-RSV) vaccine or were mock-treated. Several immunological endpoints and miR expression profiles were determined in mouse serum and bronchoalveolar lavage (BAL) following vaccine priming, boost, and RSV challenge. We identified miRs that were linked with immunological parameters of disease and protection. We show that miRs are potential biomarkers providing valuable insights for vaccine development.",

keywords = "disease, immune, microRNA, miR, RSV, vaccines",

author = "Atherton, {Lydia J.} and Jorquera, {Patricia A.} and Bakre, {Abhijeet A.} and Tripp, {Ralph A.}",

note = "Funding Information: The authors would like to thank Jeff Powell (Artificial Cell Technologies, New Haven, CT) for providing the GA2-MP vaccine. We would also like to thank Colin Williams, Ali S. Maleki, and Jackelyn Murray for assistance. Funding. This project was supported by an ARCS Foundation fellowship to LA, and the Georgia Research Alliance funding to RT. Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2019 Atherton, Jorquera, Bakre and Tripp.",

year = "2019",

month = oct,

day = "9",

doi = "10.3389/fimmu.2019.02323",

language = "English",

volume = "10",

pages = "1--16",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types

AU - Atherton, Lydia J.

AU - Jorquera, Patricia A.

AU - Bakre, Abhijeet A.

AU - Tripp, Ralph A.

N1 - Funding Information: The authors would like to thank Jeff Powell (Artificial Cell Technologies, New Haven, CT) for providing the GA2-MP vaccine. We would also like to thank Colin Williams, Ali S. Maleki, and Jackelyn Murray for assistance. Funding. This project was supported by an ARCS Foundation fellowship to LA, and the Georgia Research Alliance funding to RT. Publisher Copyright: © Copyright © 2019 Atherton, Jorquera, Bakre and Tripp.

PY - 2019/10/9

Y1 - 2019/10/9

N2 - Respiratory Syncytial Virus (RSV) causes serious respiratory tract illness and substantial morbidity and some mortality in populations at the extremes of age, i.e., infants, young children, and the elderly. To date, RSV vaccine development has been unsuccessful, a feature linked to the lack of biomarkers available to assess the safety and efficacy of RSV vaccine candidates. We examined microRNAs (miR) as potential biomarkers for different types of RSV vaccine candidates. In this study, mice were vaccinated with a live attenuated RSV candidate that lacks the small hydrophobic (SH) and attachment (G) proteins (CP52), an RSV G protein microparticle (GA2-MP) vaccine, a formalin-inactivated RSV (FI-RSV) vaccine or were mock-treated. Several immunological endpoints and miR expression profiles were determined in mouse serum and bronchoalveolar lavage (BAL) following vaccine priming, boost, and RSV challenge. We identified miRs that were linked with immunological parameters of disease and protection. We show that miRs are potential biomarkers providing valuable insights for vaccine development.

AB - Respiratory Syncytial Virus (RSV) causes serious respiratory tract illness and substantial morbidity and some mortality in populations at the extremes of age, i.e., infants, young children, and the elderly. To date, RSV vaccine development has been unsuccessful, a feature linked to the lack of biomarkers available to assess the safety and efficacy of RSV vaccine candidates. We examined microRNAs (miR) as potential biomarkers for different types of RSV vaccine candidates. In this study, mice were vaccinated with a live attenuated RSV candidate that lacks the small hydrophobic (SH) and attachment (G) proteins (CP52), an RSV G protein microparticle (GA2-MP) vaccine, a formalin-inactivated RSV (FI-RSV) vaccine or were mock-treated. Several immunological endpoints and miR expression profiles were determined in mouse serum and bronchoalveolar lavage (BAL) following vaccine priming, boost, and RSV challenge. We identified miRs that were linked with immunological parameters of disease and protection. We show that miRs are potential biomarkers providing valuable insights for vaccine development.

KW - disease

KW - immune

KW - microRNA

KW - miR

KW - RSV

KW - vaccines

UR - http://www.scopus.com/inward/record.url?scp=85074098548&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2019.02323

DO - 10.3389/fimmu.2019.02323

M3 - Article

C2 - 31649663

AN - SCOPUS:85074098548

SN - 1664-3224

VL - 10

SP - 1

EP - 16

JO - Frontiers in Immunology

JF - Frontiers in Immunology

M1 - 2323

ER -

Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types

Abstract

UN SDGs

Access to Document

Other files and links

Cite this